GLP-1 receptor agonists' impact on cardio-renal outcomes and mortality in T2D with acute kidney disease

HC Pan, JY Chen, HY Chen, FY Yeh, CY Sun… - Nature …, 2024 - nature.com
Previous studies have explored the effects of glucagon-like peptide-1 receptor agonists
(GLP-1 RAs) in reducing cardiovascular events in type 2 diabetes. Here we show that GLP-1 …

Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes

MH Chuang, JY Chen, HY Wang, ZH Jiang… - JAMA Network …, 2024 - jamanetwork.com
Importance Despite its demonstrated benefits in improving cardiovascular risk profiles, the
association of tirzepatide with mortality and cardiovascular and kidney outcomes compared …

How can inhibition of glucose and sodium transport in the early proximal tubule protect the cardiorenal system?

V Vallon - Nephrology Dialysis Transplantation, 2024 - academic.oup.com
What mechanisms can link the inhibition of sodium-glucose cotransporter 2 (SGLT2) in the
early proximal tubule to kidney and heart protection in patients with and without type 2 …

State-of-the-art-review Mechanisms of action of SGLT2 inhibitors and clinical implications

V Vallon - American Journal of Hypertension, 2024 - academic.oup.com
Inhibitors of the Na+-coupled glucose transporter SGLT2 (SGLT2i) primarily shift the
reabsorption of large amounts of glucose from the kidney's early proximal tubule to …

Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists

HW Lai, CY See, JY Chen, VC Wu - Cardiovascular Diabetology, 2024 - Springer
Abstract Background Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) have
demonstrated efficacy in improving mortality and cardiovascular (CV) outcomes. However …

[HTML][HTML] Unveiling the enigma of acute kidney disease: predicting prognosis, exploring interventions, and embracing a multidisciplinary approach

SY Pan, TTM Huang, ZH Jiang, LC Lin… - Kidney Research and …, 2024 - ncbi.nlm.nih.gov
Acute kidney disease (AKD) is a critical transitional period between acute kidney injury and
chronic kidney disease. The incidence of AKD following acute kidney injury is approximately …

[HTML][HTML] Biomarkers in pursuit of precision medicine for acute kidney injury: hard to get rid of customs

KM Lin, CC Su, JY Chen, SY Pan… - Kidney Research and …, 2024 - ncbi.nlm.nih.gov
Traditional acute kidney injury (AKI) classifications, which are centered around semi-
anatomical lines, can no longer capture the complexity of AKI. By employing strategies to …

SGLT2i treatment during AKI and its association with major adverse kidney events

L Alcantar-Vallin, JJ Zaragoza… - Frontiers in …, 2024 - frontiersin.org
Background The association between the administration of sodium–glucose cotransporter 2
inhibitors (SGLT2is) during acute kidney injury (AKI) and the incidence of major adverse …

[HTML][HTML] Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated …

CA Wang, LC Lin, JY Chen… - Cardiovascular …, 2024 - cardiab.biomedcentral.com
Sodium-glucose cotransporter 2 inhibitors (SGLT-2is) have demonstrated associations with
lowering cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM) …

Validation of a Prediction Model for Acute Kidney Injury after Cardiac Surgery in a Retrospective Asian Cohort

PH Tsai, JS Wang, CH Shen - Journal of Clinical Medicine, 2024 - mdpi.com
Background: The incidence of postoperative acute kidney injury (AKI) is relatively high in
some Asian regions. The objective of this study was to examine the performance of an AKI …